Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Fisch

Showing results (41-50 of 73) with videos related to

Pageof 8
Sort By:
Oncogene|December 1, 1992
T-cell acute lymphoblastic lymphoma induced in transgenic mice by the RBTN1 and RBTN2 LIM-domain genesP Fisch, T Boehm, I Lavenir, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 1993
Human peripheral gamma delta T cells recognize hsp60 molecules on Daudi Burkitt's lymphoma cellsI Kaur, S D Voss, R S Gupta, et al.
The New England Journal of Medicine|January 28, 1999
Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptorsR Handgretinger, A Geiselhart, A Moris, et al.
Annals of Hematology|February 2, 2015
Recurrence of persistent polyclonal B lymphocytosis (PPBL) after rituximab treatmentC Wehr, L Houet, M Pantic, et al.
Oncogene|December 1, 1994
T cell tumours of disparate phenotype in mice transgenic for Rbtn-2R C Larson, P Fisch, T A Larson, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1989
Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activationS D Voss, J A Hank, C A Nobis, et al.
Blood|May 15, 1990
Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cellsJ A Sosman, K R Oettel, S D Smith, et al.
Critical Reviews in Oncology/Hematology|January 1, 1989
The cellular immunotherapy of cancer: current and potential uses of interleukin-2P M Sondel, J A Hank, P C Kohler, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1990
Human T cell receptor-gamma delta-expressing T-cell lines recognize MHC-controlled elements on autologous EBV-LCL that are not HLA-A, -B, -C, -DR, -DQ, or -DPV Lam, R DeMars, B P Chen, et al.
Cancer Research|July 1, 1989
Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigensG Weil-Hillman, P Fisch, A F Prieve, et al.
Pageof 8

Showing results (41-50 of 73) with videos related to

Sort By:
Pageof 8
Oncogene|December 1, 1992
T-cell acute lymphoblastic lymphoma induced in transgenic mice by the RBTN1 and RBTN2 LIM-domain genesP Fisch, T Boehm, I Lavenir, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 1993
Human peripheral gamma delta T cells recognize hsp60 molecules on Daudi Burkitt's lymphoma cellsI Kaur, S D Voss, R S Gupta, et al.
The New England Journal of Medicine|January 28, 1999
Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptorsR Handgretinger, A Geiselhart, A Moris, et al.
Annals of Hematology|February 2, 2015
Recurrence of persistent polyclonal B lymphocytosis (PPBL) after rituximab treatmentC Wehr, L Houet, M Pantic, et al.
Oncogene|December 1, 1994
T cell tumours of disparate phenotype in mice transgenic for Rbtn-2R C Larson, P Fisch, T A Larson, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1989
Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activationS D Voss, J A Hank, C A Nobis, et al.
Blood|May 15, 1990
Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cellsJ A Sosman, K R Oettel, S D Smith, et al.
Critical Reviews in Oncology/Hematology|January 1, 1989
The cellular immunotherapy of cancer: current and potential uses of interleukin-2P M Sondel, J A Hank, P C Kohler, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1990
Human T cell receptor-gamma delta-expressing T-cell lines recognize MHC-controlled elements on autologous EBV-LCL that are not HLA-A, -B, -C, -DR, -DQ, or -DPV Lam, R DeMars, B P Chen, et al.
Cancer Research|July 1, 1989
Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigensG Weil-Hillman, P Fisch, A F Prieve, et al.
Pageof 8